Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 26, 2022
Reporting Period: January 2022
This filing serves as a notice to shareholders regarding the scheduling of a Special General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing.
Guidance, Outlook, and Corporate Actions
- Special General Meeting: Scheduled for March 10, 2022, at 11:00 a.m. Israel time.
- Location: 11 Hamenofim St., Building B, Herzliya, Israel.
- Exhibit: Exhibit 99.1 contains the Notice of Special General Meeting of Shareholders.
- Management Commentary: None provided regarding business outlook or risks in this specific filing.
Key Facts for Investor Verification
- Verify the agenda and specific proposals to be voted on at the Special General Meeting on March 10, 2022, by reviewing Exhibit 99.1.
- Confirm shareholder eligibility and proxy voting procedures for the upcoming meeting.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F or quarterly reports for financial metrics.